Market News AIOpen the app

RAPP stock news · Rapport Therapeutics, Inc.

Stories about Rapport Therapeutics, Inc. (RAPP) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for RAPP

Follow Rapport Therapeutics, Inc. (RAPP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RAPP
Free on the App Store and Google Play, or on the web.
  1. Oct 23, 2026, 7:00 PM ET · Market

    Goldman Sachs raised its price goal for Rapport Therapeutics from $62 to $68.

    Good for RAPP

    Goldman Sachs kept its Buy rating on Rapport Therapeutics and raised its target. This is favorable analyst opinion, but the report gives no new company results.

  2. Oct 20, 2026, 9:48 AM ET · Trial

    Rapport Therapeutics shares are up today after good news from their Phase 2 trial for RAP-219.

    Good for RAPP

    Rapport said RAP-219 met the main goal in a 3-week bipolar mania study, and a second measure also improved. The results support further testing.

  3. Oct 20, 2026, 8:14 AM ET · Market

    12 health care stocks are changing a lot before the market opens on Tuesday.

    Neutral

    Rapport Therapeutics shares rose 23.25% in Tuesday's premarket session. The article gives no company news to explain the rise, so it does not change the company's outlook.

  4. Oct 19, 2026, 8:14 AM ET · Market

    12 health care stocks are changing a lot before the market opens on Monday.

    Neutral

    Rapport Therapeutics shares rose about 12% before trading began. The story gives no reason or company news, so it does not change the company's business outlook.